UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~June~~August 133, 2023 (~~June~~July 1228, 2023)

_______________________

POINT BIOPHARMA GLOBAL INC.

(Exact name of registrant as specified in its charter)

_______________________


Delaware (State or other jurisdiction of incorporation)	001-39311 (Commission File Number)	85-0800493 (I.R.S. Employer Identification No.)
4850 West 78th Street, Indianapolis, IN, 46268
(Address of principal executive offices and zip)

(317) 543-9957

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

_______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	PNT	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 54.~~02.~~01 ~~Departure~~Changes ofin ~~Directors~~Registrant’s orCertifying ~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Accountant.

(da) Resignation ~~Appointment~~ of ~~Bridget~~independent ~~Martell~~registered aspublic ~~Class~~accounting ~~I Director of the Company~~firm.

On ~~June~~July 1228, 2023, ~~the board of directors (the “Board”) of~~ POINT Biopharma Global Inc. (the “Company”) ~~voted~~was ~~unanimously~~notified toby ~~appoint~~Armanino ~~Dr.~~LLP ~~Bridget Martell~~ (“~~Dr. Martell~~Armanino”) ~~as a Class I Director of the Company~~, ~~to fill~~ the ~~vacancy created following the expiration of Ms. Margaret E. Gilmour~~Company’s ~~term~~independent asregistered apublic ~~Class~~accounting Ifirm, ~~Director at the Company’s 2022 annual meeting~~ of ~~stockholders.~~its ~~Dr.~~decision ~~Martell’s~~to ~~initial~~cease ~~term~~providing asfinancial astatement ~~director~~audit ~~will~~services ~~expire~~to atpublic ~~the~~companies ~~Company’s~~and ~~2025~~therefore ~~annual~~it ~~meeting~~would ofbe ~~stockholders.~~resigning ~~Dr.~~as ~~Martell will serve on~~ the Company’s ~~Nominating~~independent ~~and~~registered ~~Corporate~~public ~~Governance~~accounting ~~Committee~~firm.

~~Dr.~~The ~~Martell~~resignation is aeffective ~~pharmaceutical~~upon ~~executive.~~the ~~She~~filing ~~started~~of ~~her~~the ~~pharmaceutical~~Company’s ~~career~~Quarterly atReport ~~Pfizer,~~on ~~where~~Form ~~she~~10-Q ~~had~~for ~~roles in both~~ the ~~oncology~~three- and ~~biosimilars~~six-month ~~business~~interim ~~units.~~period ~~Dr.~~ended ~~Martell~~June ~~has~~30, ~~held~~2023 ~~leadership~~after ~~roles~~which attime, ~~companies~~the ~~including~~appointment ~~Kura Oncology and Juniper Pharmaceuticals. Dr. Martell is currently President and Chief Executive Officer~~ of ~~Artizan Biosciences, Inc., a precision medicine drug development platform company focusing on inflammatory disease and~~ the ~~microbiome.~~new ~~She~~independent ~~holds~~registered apublic ~~B.Sc.~~accounting infirm ~~Microbiology~~described ~~from~~below ~~Cornell~~will ~~University,~~become ~~an M~~effective.~~A. in Molecular Immunology from Boston University, and an M.D. from the Chicago Medical School.~~

InArmanino ~~connection~~is ~~with~~not ~~her~~required ~~appointment,~~to ~~Dr.~~and ~~Martell,~~did anot ~~non-employee~~seek ~~director of~~ the Company,’s ~~will~~consent beto ~~granted~~its adecision ~~stock option award~~ to ~~purchase~~resign ~~shares~~as of the Company’s ~~common~~independent ~~stock,~~registered ~~par~~public ~~value~~accounting $0firm.~~0001~~ ~~per~~As ~~share, having an approximate value of $412,500, calculated by dividing such amount by the Black-Scholes Value as of the date of grant. On~~ a ~~go-forward basis~~result, ~~Dr.~~neither ~~Martell will be entitled to~~ the ~~standard~~Company’s ~~compensation~~Board ~~provided to non-employee directors~~ of ~~the~~Directors ~~Company,~~nor ~~as disclosed in~~ the Company’s ~~definitive~~Audit ~~proxy~~Committee ~~statement~~took onpart ~~Schedule 14A, filed by the Company with the Securities and Exchange Commission (the “SEC”) on April 27, 2023. In addition,~~ in ~~connection with her appointment, Dr. Martell will enter into the Company~~Armanino’s ~~standard~~decision ~~form indemnification agreement, a copy of which has been filed as Exhibit 10.18~~ to ~~the Current Report on Form 8-K filed by the Company with the SEC on July 1, 2021~~resign.

~~After~~Armanino ~~considering~~audited ~~all~~ the ~~relevant~~Company’s ~~facts~~consolidated ~~and~~financial ~~circumstances,~~statements ~~the Board determined that Dr. Martell qualifies~~ as anof ~~independent~~and ~~director~~for ~~under~~ the ~~applicable~~fiscal ~~listing~~years ~~standards~~ended ofDecember ~~The~~31, ~~Nasdaq~~2022 ~~Stock~~and ~~Market LLC~~2021. ~~Dr.~~The ~~Martell~~reports ~~does~~of ~~not~~Armanino ~~have~~on ~~any~~the ~~arrangement~~financial orstatements ~~understanding~~of ~~with~~the ~~any~~Company ~~other~~for ~~person~~the ~~pursuant~~fiscal toyears ~~which~~ended ~~she~~December ~~was~~31, ~~appointed~~2022 asand a2021 ~~director.~~did ~~Dr. Martell does~~ not ~~have~~contain any ~~direct~~adverse opinion or ~~indirect~~disclaimer ~~material~~of ~~interest~~opinion inand ~~any~~were ~~transaction~~not ~~required~~qualified toor bemodified ~~disclosed~~as ~~pursuant~~ to ~~Item~~uncertainty, ~~404(a)~~audit ofscope ~~Regulation~~or ~~S-K~~accounting principles.

During the Company’s fiscal years ended December 31, 2022 and 2021, and the subsequent interim period through July 28, 2023, there were no (a) disagreements between the Company and Armanino on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Armanino, would have caused Armanino to make reference to the subject matter of the disagreements in connection with its audit reports on the Company’s financial statements; or (b) “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K with respect to the Company.

The Company provided Armanino with a copy of this Current Report on Form 8-K in accordance with Item 304(a) of Regulation S-K prior to its filing with the U.S. Securities and Exchange Commission (the “Commission”) and requested that Armanino furnish the Company with a letter addressed to the Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter from Armanino is filed as Exhibit 16.1 hereto.

(b) Engagement of new independent auditor.

On August 3, 2023, the Audit Committee approved, and the Board ratified, the engagement of Deloitte & Touche LLP (“Deloitte”) and appointed Deloitte as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2023, subject to the execution of an engagement letter.

During the past two fiscal years ended December 31, 2022 and 2021, and the subsequent interim period through August 3, 2023, neither the Company nor anyone on the Company’s behalf consulted with Deloitte with respect to either (i)(a) the application of accounting principles to a specified transaction, either completed or proposed, or (b) the type of audit opinion that might be rendered on our financial statements, and no written report nor oral advice was provided to the Company that Deloitte concluded was an important factor that the Company consider in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any other matter that was the subject of a "disagreement" (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined above).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Number

Exhibit

16.1

Letter from Armanino LLP, dated August 3, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 13, 2023	POINT BIOPHARMA GLOBAL INC.
Dated: August 3, 2023	POINT BIOPHARMA GLOBAL INC.
	By:	/s/ Bill Demers
	Name:	Bill Demers
	Title:	Chief Financial Officer

Filing Compare · POINT Biopharma Global Inc.